Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Todd Franklin Watanabe
- Employees
- 354
- Market cap
- $3.6 B
- IPO
- 31/01/2020
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm in the Healthcare sector dedicated to developing and marketing therapies for a range of skin-related diseases. The company is headquartered in Westlake Village, US, and is listed on the NASDAQ. Established in 2016 as Arcutis, Inc., the company changed its name…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Arcutis Biotherapeutics stock: price history
1D
-1.0%
1W
+8.4%
1M
+10.3%
6M
+17.5%
YTD
-0.8%
1Y
+37.8%
2Y
+196.5%
5Y
+29.4%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~18% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Arcutis Biotherapeutics
Analyst assessment of Arcutis Biotherapeutics
PRICE TARGET LOW
US$38.00
CONSENSUS
US$40.75
MEDIAN
US$38.50
PRICE TARGET HIGH
US$48.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 06/08/2026
Arcutis Biotherapeutics stock metrics
P/E
130.53
P/B
17.05
EV/EBITDA
85.25
RETURN ON EQUITY
6.8%
NET MARGIN
11.6%
DEBT/EQUITY
0.52
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.1%
FLOAT SHARES
109,507,144
AVG. DAILY VOLUME (30D)
3,099,980
Insider transactions (SEC)
Matsuda Masaru
Welgus Howard G.
Welgus Howard G.
Welgus Howard G.
Welgus Howard G.
Institutional holders
Comparable stocks
Frequently asked questions about Arcutis Biotherapeutics stock
What does Arcutis Biotherapeutics do?
Arcutis Biotherapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Todd Franklin Watanabe, the company employs around 354 people.
The IPO was on 31/01/2020; the stock trades on NASDAQ under the ticker ARQT.
What do analysts say about Arcutis Biotherapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 06/08/2026).
The average price target is US$40.75, ranging from US$38.00 to US$48.00, with a median of US$38.50.
This is an external assessment, not a statement by Market Jury.
When does Arcutis Biotherapeutics report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Arcutis Biotherapeutics pay a dividend?
No, Arcutis Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Arcutis Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arcutis Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arcutis Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.